Literature DB >> 16322282

Expression of interleukin-9 in nasal natural killer/T-cell lymphoma cell lines and patients.

Toshihiro Nagato1, Hiroya Kobayashi, Kan Kishibe, Miki Takahara, Takeshi Ogino, Hideyuki Ishii, Kensuke Oikawa, Naoko Aoki, Keisuke Sato, Shoji Kimura, Norio Shimizu, Masatoshi Tateno, Yasuaki Harabuchi.   

Abstract

PURPOSE: Nasal natural killer (NK)/T-cell lymphoma is associated with EBV and has distinct clinical and histologic features. However, little is known about its genetic features. In this study, we examined the genes expressed by SNK-6 and SNT-8 cells, which were established from nasal NK/T-cell lymphomas, and found that interleukin (IL)-9 was specifically expressed in these two cell lines. EXPERIMENTAL
DESIGN: cDNA array was used to examine the genes expressed by SNK-6 and SNT-8 cells. Expression of IL-9 and IL-9 receptor was investigated by reverse transcription-PCR, ELISA, and flow cytometry. Cell growth was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Immunohistologic staining and ELISA were used to examine IL-9 expression in biopsies and sera from patients, respectively.
RESULTS: In cDNA array, expression of IL-9 mRNA was much higher in SNK-6 and SNT-8 cells than in NK-92 cells from non-nasal NK-cell lymphoma and peripheral blood mononuclear cells from healthy volunteers. Furthermore, IL-9 was specifically expressed by SNK-6 and SNT-8 cells but not by other NK-cell, NK-like T-cell, and T-cell lymphoma/leukemia cell lines. IL-9 receptor was also expressed on the surfaces of SNK-6 and SNT-8 cells. An IL-9-neutralizing antibody inhibited the growth of these two cell lines, whereas recombinant human IL-9 enhanced their growth. Most significantly, IL-9 was present in biopsies and sera from patients with this lymphoma.
CONCLUSIONS: These results suggest that IL-9 plays an important role in nasal NK/T-cell lymphoma possibly via an autocrine mechanism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322282     DOI: 10.1158/1078-0432.CCR-05-1426

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  28 in total

Review 1.  Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL).

Authors:  Bradley M Haverkos; Carrie Coleman; Alejandro A Gru; Zenggang Pan; Jonathan Brammer; Rosemary Rochford; Anjali Mishra; Christopher C Oakes; Robert A Baiocchi; Aharon G Freud; Pierluigi Porcu
Journal:  Discov Med       Date:  2017-03       Impact factor: 2.970

Review 2.  The use of biologics for immune modulation in allergic disease.

Authors:  Willem van de Veen; Mübeccel Akdis
Journal:  J Clin Invest       Date:  2019-03-18       Impact factor: 14.808

3.  Inhibition of adaptive immunity by IL9 can be disrupted to achieve rapid T-cell sensitization and rejection of progressive tumor challenges.

Authors:  Dominique B Hoelzinger; Ana Lucia Dominguez; Peter A Cohen; Sandra J Gendler
Journal:  Cancer Res       Date:  2014-10-08       Impact factor: 12.701

4.  Increased serum levels of interleukin-15 correlate with negative prognostic factors in extranodal NK/T cell lymphoma.

Authors:  Hua Wang; Jia-Yu Zhu; Cheng-Cheng Liu; Meng-Yuan Zhu; Jing-Hua Wang; Qi-Rong Geng; Yue Lu
Journal:  Med Oncol       Date:  2014-11-27       Impact factor: 3.064

Review 5.  Cellular sources and immune functions of interleukin-9.

Authors:  Randolph J Noelle; Elizabeth C Nowak
Journal:  Nat Rev Immunol       Date:  2010-09-17       Impact factor: 53.106

Review 6.  [Primary nasal natural killer/T-cell lymphomas: classification and clinicopathological features].

Authors:  A Sandner; S Kösling; P Helmbold; M Winkler; M B Bloching; H-J Holzhausen
Journal:  HNO       Date:  2007-02       Impact factor: 1.284

7.  Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients.

Authors:  Yumi Nonomura; Atsushi Otsuka; Chisa Nakashima; Judith A Seidel; Akihiko Kitoh; Teruki Dainichi; Saeko Nakajima; Yu Sawada; Shigeto Matsushita; Megumi Aoki; Tatsuya Takenouchi; Taku Fujimura; Naohito Hatta; Satoshi Koreeda; Satoshi Fukushima; Tetsuya Honda; Kenji Kabashima
Journal:  Oncoimmunology       Date:  2016-10-18       Impact factor: 8.110

8.  Role of high expression of IL-9 in prognosis of CLL.

Authors:  Na Chen; Xiao Lv; Peipei Li; Kang Lu; Xin Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

9.  Overexpression of IL-9 induced by STAT6 activation promotes the pathogenesis of chronic lymphocytic leukemia.

Authors:  Na Chen; Kang Lu; Peipei Li; Xiao Lv; Xin Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

10.  CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.

Authors:  Takumi Kumai; Toshihiro Nagato; Hiroya Kobayashi; Yuki Komabayashi; Seigo Ueda; Kan Kishibe; Takayuki Ohkuri; Miki Takahara; Esteban Celis; Yasuaki Harabuchi
Journal:  Cancer Immunol Immunother       Date:  2015-03-10       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.